| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c360c53969e3636a28241f5969a403e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fccc5dcb3ef9aa08b3e1c4884a8c4e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_671aeebb86f2583b8e799565cdc6fc44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a546384a5eedf2f5c8026fc8dd0ac6d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate |
1999-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca9dbf573c23a808a6d5f86f24ddcbbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3b851ec6da9818877df8c3a60d7b4ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01d8665f5cb40e32fe5dc1a19d344cce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5b919bc4e04f1de48f42bd48231870e |
| publicationDate |
2000-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0011470-A1 |
| titleOfInvention |
Method for screening candidate compounds for drug against tumor |
| abstract |
As the results of studies on the appearance frequency of FLT3/ITD in various hematopoietic tumors, it is found out that a particularly high frequency thereof is observed in acute myeloblastic leukemia. As the results of studies on the function of FLT3/ITD in a blood cell line, it is found out that the tyrosine residue of FLT3/ITD is commonly phosphorylated in this cell line and that blood cells having FLT3/ITD transferred thereinto show IL3-independent proliferation. It is moreover found out that blood cells having FLT3/ITD transferred thereinto are capable of forming tumor and show regulated cell differentiation. It is possible to screen medicinal compounds for tumor on the basis of these functions of FLT3/ITD as indication. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8138159-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02057847-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005035004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012508367-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2005035004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2727195-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4486928-B2 |
| priorityDate |
1998-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |